Clinical Effect And Safety Of Anlotinib In The Maintenance Treatment Of Extensive Small Cell Lung Cancer

Background and ObjectiveSmall cell lung cancer(SCLC)is a malignant tumor with high malignancy,strong invasiveness,rapid growth rate and early metastasis.It has a high incidence in China and can account for 10%-15% of new lung cancer in China.Although it is sensitive to first-line radiotherapy and chemotherapy,but it still has high recurrence rate,short survival,poor prognosis.Since Dr.Folkman discovered the relationship between tumor and neovascularization in 1971,it is believed that the new blood vessels can provide the nutrients necessary for tumor growth,and play a vital role in tumor growth and metastasis.In recent years,with the discovery of molecular pathways for angiogenesis,targeted therapy against angiogenesis has gained worldwide attention.A large number of clinical trials have confirmed the significant efficacy of anti-vascular targeting drugs for malignant tumors.Anlotinib is a new type of small molecule multi-target anti-vascular targeting drug independently developed by China,and has achieved remarkable effects in clinical trials of various tumors.This study evaluated the efficacy and safety of anlotinib by observing the relevant indicators of the maintenance treatment of anlotinib in small cell lung cancer.MethodsA total of 40 patients with extensive small cell lung cancer were enrolled in the study.They were randomized into two groups,including 20 patients in the anlotinib maintenance group and 20 patients in the observation group.The treatment group received anlotinib for maintenance treatment after first-line chemotherapy,and the observation group was reviewed regularly.Progression-free survival,KPS scores,NSE status,the physical status of the patients before and after treatment and adverse reactions were observed in the two groups ResultsAfter 2-6 cycles of treatment,the survival situation,KPS score,serum NSE level and adverse reactions were evaluated.The mPFS of the anlotinib group was 5.2months(95% confidence interval 5.0 to 5.4),and the mPFS of the observation group was 3.1 months(95% confidence interval 2.8 to 3.4).The data of the two groups were statistically significant.(P<0.05).The KPS score and NSE of the anlotinib group were improved compared with the observation group.In terms of safety assessment,a grade 3/4 adverse reaction in the anlotinib group was a case of hand-foot skin reaction,which was improved after adjusting the dose,and no adverse events such as drug-related death occurred.The incidence of total adverse reactions in the two groups.There was no statistically significant difference in the incidence of adverse events at grade 3/4.ConclusionThe use of anlotinib for the maintenance treatment of SCLC can prolong the progression-free survival of patients,improve quality of life,and be safe and well tolerated.